Solid Tumors

Latest News

FDA Updates: Assays Used in Cancer Care Get Green Light
FDA Updates: Assays Used in Cancer Care Get Green Light

August 9th 2020

Adaptive Biotechnologies’ clonoSEQ gets third approval; FDA also acts on first at-home treatment for spinal muscular atrophy.

Keytruda Approved for Early Treatment of Colorectal Cancer in Patients With Genetic Mutations
Keytruda Approved for Early Treatment of Colorectal Cancer in Patients With Genetic Mutations

June 30th 2020

Rising drug costs
Payers Should Take Action on Rising NSCLC Costs

November 29th 2019

Cancer patient
Chemotherapy Remains Significant for Cancer Treatment

November 29th 2019

TCells Attacking
Personalized Treatments Could Increase Value of Cancer Care

November 25th 2019

Latest CME Events & Activities

Advancing Precision Care Through Biomarker-Driven Therapy: CEACAM5 as a Therapeutic Target in NSCLC

View More

Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers

View More

2023 IASLC North America Conference on Lung Cancer Satellite Symposia

Register Now!

Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care

View More

Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care

View More

Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers

View More

Show Me Your Care Plan™: Monitoring and Managing Patients With EGFR Exon20 Insertion+ NSCLC

View More

Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow

View More

Community Practice Connections™: 17th Annual New York Lung Cancers Symposium

View More

Trekking Through the Latest Updates for ROS1-Targeted Therapies

View More

Navigating the Latest Data on NTRK-Targeted Therapies

View More

40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®

View More

Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC

View More

Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care

View More

21st Annual Winter Lung Cancer Conference®

Register Now!

Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse

View More

The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward

View More

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

View More

On-Demand Video Updates from the Annual Oncology Meeting

View More

Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC

Martin F. Dietrich, MD, PhD; Neil A. Abrahams, MD; Shirley M. Shiller, DO, AP/CP, MGP, FACP

View More

Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?

View More

Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

Register Now!

More News

© 2023 MJH Life Sciences

All rights reserved.